厄洛替尼单药一线治疗非小细胞肺癌的研究进展

Advanced in search for erlotinib as the first-line monotherapy for non-small cell lung cancer

高效低毒的分子靶向治疗药物厄洛替尼,在非小细胞肺癌(NSCLC)的二、三线治疗以及序贯和维持治疗中,已经显示出其能够使患者临床获益。厄洛替尼单药为晚期NSCLC的一线治疗新的选择方案。本文就其在老年、体力状态较差、不吸烟以及存在表皮生长因子(EGFR)敏感性突变或K-ras耐药突变的NSCLC患者中的应用作一综述。

The molecular targeted therapy drug erlotinib, with property of high- performance and low toxicity, has been shown to benefit the survival of patients in the second and third -line treatment, as well as sequential and maintenance therapy of non- small -cell lung cancer （NSCLC）. Recently, the results of clinical trials about erlotinib as first -line monotherapy for the selective patients have provided new options for the first - line treatment of advanced NSCLC. In this paper, we make a review about progress of recent clinical trials of elotinib as first - line monotherapy for the elder patients, patients with poor physical status, non -smoking patients, epidermal growth factor receptor（EGFR） sensitive mutations or K- ras resistant mutation.